Bluejay IPO Presentation Deck

Board of Directors* Douglas C. Wurth Chairman Indranil "Neil" Dey CEO Svetlana Dey Donald R. Chase Fred S. Zeidman 20 year career at J.P. Morgan Chase, including CEO of the International Private Bank and CEO of the Alternative Investments division of Asset Management General Counsel to Senator Robert Dole's 1996 Presidential Campaign, practiced law at Skadden, Arps, Meagher and Flom B.A Notre Dame University; J.D. University of Virginia School of Law Skadden 25+ years in healthcare industry (pharma & diagnostics) • Involved in introducing Her2neu test for Herceptin (>$1.2 billion revenue) and introduction of Erbitux (>$1.15 billion revenue) Ph.D. in Biochemistry (UNESCO fellow) from BRC, Hungary and MBA (Fulbright Scholar) from Cambridge University, UK More than 15 years of management experience in healthcare industry Co-founder of Bluejay, President & CEO of LMBRI LLC, Board Member of Laminar Pharma, Inc. Masters Degree in Mathematics from the State University of Mari El Republic, Russia 35 years, President & CEO West Bank Corporation, Multi State Community Bank, Mass Chairman, NUVO Bank, DeNovo Bank, Springfield, Mass, Merchants Bank, Director Millyard Bank, N.H. Bachelor of Science Degree, Accounting, Western New England University, Springfield, Mass, 50+ years of corporate advisory experience Chairman Emeritus Gordian Group, Chairman Emeritus University of Texas Health Science System Bachelor's degree from Washington University in St. Louis and a Master's in Business Administration from New York University J.P.Morgan Imbri bluejay Gary Gemignani has agreed to join the Board upon the completion of the IPO IMPATH LAMINAR PHARMA merchants BANCSHARES INC westbank HOLOCAUST MUSEUM Copyright 2021 Bluejay Diagnostics, Inc. All rights reserved in all slides | October 2021 17

View entire presentation